The ARB Family
Angiotensin II Receptor Blockers — Biphenyl-Tetrazole SAR
## Overview
Angiotensin II receptor blockers (ARBs) directly block the AT1 receptor subtype, preventing angiotensin II-mediated vasoconstriction, aldosterone release, and renal sodium retention. Unlike ACE inhibitors, they do not inhibit bradykinin inactivation, avoiding ACE inhibitor-related dry cough (which occurs in up to 15-20% of ACE inhibitor users). Losartan was the first ARB approved (1995), emerging from DuPont's medicinal chemistry program that converted the peptide angiotensin II antagonist S-8308 into an orally active small molecule.
## From Peptide to Small Molecule
Early angiotensin II antagonists were peptides (saralasin) with poor oral bioavailability and partial agonist activity. A key SAR breakthrough was the discovery that a biphenyl group could mimic the phenylalanine residue (Phe8) of the C-terminus of angiotensin II. Attaching an imidazole heterocycle to the biphenyl (resembling the His6 of angiotensin II) gave the first non-peptide antagonist with measurable AT1 affinity. The critical advance was replacing the carboxylate bioisostere with a tetrazole (S-8307 → losartan precursors): the tetrazole's higher pKa (~6) compared to carboxylate (~4.5) improves ionization at physiological pH and lipophilicity.
## Tetrazole as Carboxylate Bioisostere
The 1H-tetrazol-5-yl group is a well-established carboxylate bioisostere. Its pKa (~4.5-5.5 depending on substitution) is similar to carboxylate, it is planar and negatively charged at physiological pH, and it is more lipophilic than carboxylate (logP increases by ~1 unit). In ARBs, the tetrazole engages the Lys199 and Arg167 residues of AT1. Losartan's tetrazole is responsible for its superior oral bioavailability compared to the analogous carboxylic acid.
## Ortho-Alkyl Substituent
An ortho-positioned alkyl chain on the biphenyl is universally required for AT1 binding. In losartan, a butyl group is optimal; shorter (ethyl) or longer (hexyl) chains reduce potency. This chain occupies a narrow hydrophobic groove between TM3 and TM7 of AT1. In irbesartan and olmesartan, the alkyl is incorporated into a bicyclic ring (cyclopentyl-imidazolone and imidazoline, respectively), providing conformational restriction and slightly increased potency.
## Surmountable vs Insurmountable Antagonism
Losartan and valsartan produce surmountable AT1 blockade: at sufficiently high angiotensin II concentrations, they can be displaced. Candesartan, olmesartan, and irbesartan exhibit insurmountable antagonism (also called competitive antagonism with very slow dissociation). Candesartan achieves this through two anionic groups (tetrazole + benzimidazole carboxylate) making bivalent interactions with AT1 that dissociate extremely slowly. This may contribute to more consistent 24-hour blood pressure control.
## Hepatic Activation (Losartan)
Losartan is a prodrug in an unusual sense: its chlorobiphenyl imidazole metabolite EXP-3174 (formed by CYP2C9/CYP3A4-mediated oxidation of the hydroxymethyl group to carboxylate) is 10-40x more potent at AT1 and accounts for the majority of losartan's pharmacodynamic effect. This is a rare case of metabolic activation within the same drug class.
## Key Takeaways
- Biphenyl-tetrazole scaffold mimics the C-terminal phenylalanine-carboxylate of angiotensin II
- Tetrazole is the preferred carboxylate bioisostere (higher pKa → better ionization, higher lipophilicity)
- Ortho-alkyl on biphenyl is essential for AT1 selectivity; chain length ~4-5 carbons is optimal
- Candesartan/olmesartan achieve insurmountable antagonism via bivalent anionic binding
- Telmisartan's benzimidazole extension provides uniquely long half-life and PPAR-gamma activity
SAR Summary
Key SAR findings for the ARB family:
- Biphenyl-tetrazole is the core of losartan; the tetrazole bioisostere of carboxylate is critical for AT1 binding (pKa ~6 vs carboxylate pKa ~4.5, providing better protonation state at physiological pH).
- An ortho-linked alkyl group (butyl in losartan, valyl/pentyl in valsartan) is required; it occupies a hydrophobic pocket at the AT1 receptor.
- Chloro substituent at para-position on the biphenyl increases potency via hydrophobic interaction with Phe182 and Leu202.
- Imidazole ring (losartan) can be replaced by acylsulfonamide (valsartan) or other electron-poor heterocycles while retaining activity.
- Non-surmountable (insurmountable) antagonism of candesartan and olmesartan arises from very slow dissociation (covalent-like binding), conferred by their tetrazole with an additional carboxylate.
- Telmisartan's benzimidazole extension gives very long half-life and high lipophilicity for once-daily dosing.